Aspirin/dipyridamole extended release

Drug Profile

Aspirin/dipyridamole extended release

Alternative Names: Aggrenox; Asasantin; Asasantin 200/25 Retard; Asasantin Retard; Asasantin SR; Dipyridamole-extended release/aspirin

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antiplatelets; Salicylates; Small molecules; Vasodilators
  • Mechanism of Action Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Stroke; Transient ischaemic attacks

Most Recent Events

  • 01 Jul 2015 Generic equivalent available in USA for Stroke (Prevention)
  • 14 May 2008 Efficacy and safety data from the PRoFESS trial released by Boehringer Ingelheim ,
  • 28 Mar 2006 Phase-III clinical trials in Stroke in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top